A Phase III Multi-National, Multi-Site, Double Blind Placebo-Controlled, Parallel Group, 36 Week Study to Assess the Efficacy and Safety of the Engineered Human Anti-TNFa Antibody, CDP571, to Prevent Disease Flare Whilst Allowing Steroid...

  • De Villiers, Willem (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date6/15/015/14/04